Recently, a case–control study [45] demonstrated that Serpina4 was down-regulated in the liver of obese NAFLD patients and plays critical roles in the inhibition of inflammation and oxidative stress. Here, SERPINA4 is linked to metabolic dysfunction-associated steatotic liver disease.